Trial of Apremilast for Oral Ulcers in Behçet's Syndrome.

Gülen HatemiAlfred Daniel MahrYoshiaki IshigatsuboYeong-Wook SongMitsuhiro TakenoDoyoung KimMelike MelikoğluSue ChengShannon McCueMaria ParisMindy ChenYusuf Yazici

Published in: The New England journal of medicine (2019)

In patients with oral ulcers associated with Behçet's syndrome, apremilast resulted in a greater reduction in the number of oral ulcers than placebo but was associated with adverse events, including diarrhea, nausea, and headache. (Funded by Celgene; ClinicalTrials.gov number, NCT02307513.).

Keyphrases

phase iii
clinical trial
study protocol
wound healing
randomized controlled trial
phase ii
double blind
placebo controlled